Veradermics MANE
Veradermics, Inc · NYSE · Pharmaceutical Preparations
$143.83+2.21%close on Oct. 28, 2026 · volume 396K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 19, 2026 | Montanova Capital LLC with Aaron Cowen, Averill Master Fund Ltd., Averill Madison Master Fund Ltd. director · indirect | Sold | 750,000 | $107.25 | $80.44 million |
| Aug. 17, 2026 | Timothy August Durso Chief Technical Officer | Sold 10b5-1 plan | 43,500 | $107.82 $106.71-$111.28 | $4.69 million |
| Aug. 17, 2026 | Reid Alexander Waldman Chief Executive Officer, director | Sold 10b5-1 plan | 67,500 | $107.86 $106.72-$111.28 | $7.28 million |
| Aug. 12, 2026 | John W. Childs director · indirect | Sold | 100,000 | $107.12 $106.14-$108.24 | $10.71 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 13 →Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedVeradermics (NYSE: MANE) Reports Positive Phase 3 Study 304 Topline: VDPHL01 Achieves 28.6 and 36.4 hairs/cm² TAHC Gains vs. 6.6 Placebo